Sign up for free psoriasis treatment tips by email.

EMAIL ADDRESS:


Find us on Facebook




Latest News

SEE ALLOur Sponsors




Voclosporin

BRAND NAME: n/a
GENERIC NAME: voclosporin
EXPERIMENTAL/INTERNAL COMPANY NAME: ISA247
TESTING PHASE
III


DRUG USE (P OR PsA)METHOD OF DELIVERYDEVELOPING COMPANY/COMPANIES
Moderate to severe psoriasisPillIsotechnika / Lux Biosciences


Description and Comments

Voclosporin is a calcineurin inhibitor, like cyclosporin, that is being designed with the hope of achieving comparable effectiveness to cyclosporin with fewer side effects.  Kidney damage, for example, limits the use of cyclosporin to brief periods of time (typically one year).

Voclosporin has completed Canadian/European Phase Three study in moderate to severe psoriasis. While it appeared to have a better safety profile than cyclosporin (at least for the limited duration of the study), it improved psoriasis symptoms in significantly fewer patients.

Voclosporin (formerly called ISA247, and called Luveniq as a treatment for eye disease), is also being studied for the prevention of rejection following kidney transplant, and in uveitis, an eye disorder, among other possible uses.

Stock in Isotechnika dropped in August 2010 after the U.S. Food and Drug Administration (FDA) asked for an additional Phase Three trial in non-infectious uveitis.

Other News and Links

FDA wants additional trial of voclosporin for eye disease. August 2010

Voclosporin vs. cyclosporin head-to-head study results. May 2009

Voclosporin/ISA247 European/Canadian Phase Three study results. April 2008
© 2005-2014 Psoriasis Cure Now WEB DESIGN BY SKYHOOK MARKETING